We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+37.76%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$266M
AUM Growth
+$124M
Cap. Flow
+$35.3M
Cap. Flow %
13.24%
Top 10 Hldgs %
99.39%
Holding
14
New
3
Increased
6
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$12.4M
2
RGNX icon
Regenxbio
RGNX
+$10.6M
3
PRQR icon
ProQR Therapeutics
PRQR
+$8.5M
4
PVLA
Palvella Therapeutics
PVLA
+$6.96M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.8M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$8.74M

Sector Composition

Rank Sector Weight
1 Healthcare 55.35%
2 Miscellaneous 44.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$119M 44.66%
1,250,000
+750,000
+150% +$64.9M
QURE icon
2
uniQure
QURE
$2.66B
$28.4M 10.68%
396,899
+5,700
+1% +$313K
PRQR icon
3
ProQR Therapeutics
PRQR
$241M
$19.1M 7.16%
1,922,570
+1,090,909
+131% +$8.5M
PVLA
4
Palvella Therapeutics
PVLA
$2.1B
$17.8M 6.67%
62,085
+25,107
+68% +$6.96M
XENE icon
5
Xenon Pharmaceuticals
XENE
$3.69B
$15.3M 5.75%
1,166,736
+215,209
+23% +$2.26M
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.99B
$14.9M 5.59%
71,967
+15,127
+27% +$2.8M
MRUS
7
DELISTED
Merus
MRUS
$14.6M 5.49%
1,038,746
– –
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$13.5M 5.08%
+614,436
New +$12.4M
SPRO icon
9
Spero Therapeutics
SPRO
$72.8M
$11.1M 4.17%
1,154,356
– –
RGNX icon
10
Regenxbio
RGNX
$478M
$11M 4.14%
+268,778
New +$10.6M
FATE icon
11
Fate Therapeutics
FATE
$279M
$1.41M 0.53%
72,273
– –
MOR
12
DELISTED
MorphoSys AG American Depositary Shares
MOR
$217K 0.08%
+6,080
New +$182K
BCYC
13
Bicycle Therapeutics
BCYC
$261M
– –
-767,026
Closed -$8.74M
QURE icon
14
CALL
uniQure
QURE
$2.66B
– –
-400,000
Closed -$15.7M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Aquilo Capital Management held 14 positions worth $266M, up 87% from $142M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aquilo Capital Management deployed $35.3M of net new capital in Q4 2019, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 614,436 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 62% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was Bicycle Therapeutics, an estimated $8.74M sold.

  • Aquilo Capital Management's largest Q4 2019 buy was Dicerna Pharmaceuticals, Inc.: 614,436 shares worth $13.5M.
  • Aquilo Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $8.5M increase.
  • Aquilo Capital Management fully exited Bicycle Therapeutics in Q4 2019, selling an estimated $8.74M.
  • Aquilo Capital Management's ten largest holdings make up 99% of its $266M portfolio in Q4 2019.
  • Aquilo Capital Management opened 3 new positions and closed 2 in Q4 2019.
  • Aquilo Capital Management's portfolio value rose 87% quarter-over-quarter to $266M.

Based on Aquilo Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.